ArticleCell2021
Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques.
Open access · bronzeAbstract read
In one paragraph
Article in Cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Risk Factors for Weak Antibody Response of SARS-CoV-2 Vaccine in Adult Solid Organ Transplant Recipients: A Systemic Review and Meta-Analysis.Frontiers in immunology · 2022Pooled it
- Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial.Nature microbiology · 2022Trial
- Exposure route, not dose, is the primary driver of infection patterns for a respiratory virus.Science advances · 2026Article
- Industry Perspective on Translational and Clinical Pharmacology Aspects of Viral-based Gene Therapies and Vaccines-Key Considerations and Learnings From Approved Products.The AAPS journal · 2026Review
- Early innate immune signatures correlate with Ad26.COV2.S vaccine durability and protective efficacy.bioRxiv : the preprint server for biology · 2026Article
- Correlates of severe and delta COVID-19 in a phase 3 trial of the AZD1222 vaccine.NPJ vaccines · 2026Article
- Exposure route drives SARS-CoV-2 infection patterns in non-human primates.bioRxiv : the preprint server for biology · 2026Article
- Review
- When less is statistically Equivalent: Lobe-Specific optimization of histopathological assessment in SARS-CoV-2 pneumonia.Computers in biology and medicine · 2025Article
- Next-Generation Adenoviral Vector-Based Vaccines for Severe Acute Respiratory Syndrome Coronavirus-2.Vaccines · 2025Review
- A systems biology approach to define SARS-CoV-2 correlates of protection.NPJ vaccines · 2025Article
- Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates.Nature immunology · 2024Article
- Safety and Immunogenicity Study of a Bivalent Vaccine for Combined Prophylaxis of COVID-19 and Influenza in Non-Human Primates.Vaccines · 2024Article
- Review
- Activation of coagulation and proinflammatory pathways in thrombosis with thrombocytopenia syndrome and following COVID-19 vaccination.Nature communications · 2023Article
- Proceedings of the 2023 Division of Translational Toxicology Satellite Symposium.Toxicologic pathology · 2023Article
- BCG administration promotes the long-term protection afforded by a single-dose intranasal adenovirus-based SARS-CoV-2 vaccine.iScience · 2023Article
- Comparative analysis of spike-specific IgG Fc glycoprofiles elicited by adenoviral, mRNA, and protein-based SARS-CoV-2 vaccines.iScience · 2023Article
- A replicon RNA vaccine can induce durable protective immunity from SARS-CoV-2 in nonhuman primates after neutralizing antibodies have waned.PLoS pathogens · 2023Article
- Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine.NPJ vaccines · 2023Article
Corrections and comments
- Update of
Authors and funding
33 authors at 4 institutions in 2 countries.
Xuan HeCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Abishek ChandrashekarCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Roland ZahnJanssen Vaccines & Prevention BV, Leiden, the Netherlands.
Frank WegmannJanssen Vaccines & Prevention BV, Leiden, the Netherlands.
Jingyou YuCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Noe B MercadoCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Katherine McMahanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Amanda J MartinotTufts University Cummings School of Veterinary Medicine, North Grafton, MA 01536, USA.
Cesar Piedra-MoraTufts University Cummings School of Veterinary Medicine, North Grafton, MA 01536, USA.
Sidney BeecyTufts University Cummings School of Veterinary Medicine, North Grafton, MA 01536, USA.
Sarah DucatTufts University Cummings School of Veterinary Medicine, North Grafton, MA 01536, USA.
Ronnie ChamanzaJanssen Vaccines & Prevention BV, Leiden, the Netherlands.
Sietske Rosendahl HuberJanssen Vaccines & Prevention BV, Leiden, the Netherlands.
Marjolein van HeerdenJanssen Vaccines & Prevention BV, Leiden, the Netherlands.
Leslie van der FitsJanssen Vaccines & Prevention BV, Leiden, the Netherlands.
Erica N BorducchiCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Michelle LiftonCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Jinyan LiuCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Felix NampanyaCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Shivani PatelCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Lauren PeterCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Lisa H TostanoskiCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Laurent PessaintBioqual, Rockville, MD 20852, USA.
Alex Van RyBioqual, Rockville, MD 20852, USA.
Brad FinneyfrockBioqual, Rockville, MD 20852, USA.
Jason VelascoBioqual, Rockville, MD 20852, USA.
Elyse TeowBioqual, Rockville, MD 20852, USA.
Renita BrownBioqual, Rockville, MD 20852, USA.
Anthony CookBioqual, Rockville, MD 20852, USA.
Hanne AndersenBioqual, Rockville, MD 20852, USA.
Mark G LewisBioqual, Rockville, MD 20852, USA.
Hanneke SchuitemakerJanssen Vaccines & Prevention BV, Leiden, the Netherlands.
Dan H BarouchCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA; Massachusetts Consortium on Pathogen Readiness, Boston, MA 02215, USA. Electronic address: dbarouch@bidmc.harvard.edu.
Beth Israel Deaconess Medical Center · USBioqual · USJanssen (Netherlands) · NLTufts University · US
Funding
Consortia for Innovative AIDS Research in Nonhuman PrimatesUM1AI124377 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H., PICKER, LOUIS J. · 2016 to 2021
$53.0MCombined Immunologic Approaches to Cure HIV-1UM1AI126603 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H., MELLORS, JOHN W · 2016 to 2020
$23.6MProject 2U19AI128751 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H. · 2018 to 2022
$14.0MImpact of the Intestinal Microbiome on HIV/SIV VaccinesR01OD024917 · OD · WASHINGTON UNIVERSITY · PI BALDRIDGE, MEGAN T, BAROUCH, DAN H. · 2017 to 2021
$4.3MImmunologic Signatures of SARS-CoV-2 Vaccination and DiseaseU01CA260476 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H. · 2020 to 2024
$3.7MOptimization of Broadly Neutralizing Antibodies for HIV EradicationR01AI129797 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H. · 2017 to 2021
$3.6MHigh-Throughput TB Vaccine Antigen DiscoveryK08AI135098 · NIAID · TUFTS UNIVERSITY BOSTON · PI MARTINOT, AMANDA · 2018 to 2022
$931kNCI NIH HHS U01 CA260476NIAID NIH HHS K08 AI135098NIAID NIH HHS R01 AI129797NIAID NIH HHS U19 AI128751NIAID NIH HHS UM1 AI124377NIAID NIH HHS UM1 AI126603NIH HHS R01 OD024917
Abstract
We previously reported that a single immunization with an adenovirus serotype 26 (Ad26)-vector-based vaccine expressing an optimized SARS-CoV-2 spike (Ad26.COV2.S) protected rhesus macaques against SARS-CoV-2 challenge. To evaluate reduced doses of Ad26.COV2.S, 30 rhesus macaques were immunized once with 1 × 10
Indexed as
AdenoviridaeAnimalsAntibodies, NeutralizingAntibodies, ViralB-LymphocytesCOVID-19COVID-19 VaccinesFemaleImmunogenicity, VaccineImmunologic MemoryMacaca mulattaMaleSARS-CoV-2Spike Glycoprotein, CoronavirusVaccinationViral VaccinesAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesSpike Glycoprotein, CoronavirusViral VaccinesAd26.COV2.SCOVID-19humoral immunityimmunologymemory B cellsnon-human primatesprotectionSARS-CoV-2vaccination
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.